accepted%20track%20change-TLRsinCADauthorrevised-Final.pdf (834.52 kB)
Toll-like receptors signaling pathways as a potential therapeutic target in cardiovascular disease
journal contribution
posted on 2023-06-20, 14:17 authored by Seyed Mostafa Parizadeh, Maryam Ghandehar, Motahareh Heydari-Majd, Sima Seifi, Ramin Mardani, Seyed Mohamahdreza Parizadeh, Majid Ghayour-Mobarhan, Gordon FernsGordon Ferns, Seyed Mahdi Hassanian, Amir AvanCardiovascular disease (CVD) is one of the most important causes of morbidity and mortality, and associated with an important economic burden globally. Over the last decade, the prevalence of CVD has been rising globally, and is now associated with millions of death annually in both developed and developing countries. There is good evidence that the immune system is involved in the pathophysiology of CVD. Toll-like receptors (TLRs) and their down-stream signaling pathways play an important role in the immune system. Recent studies have suggested that the TLRs are involved in atherogenesis, including stroke, myocardial infarction, ischemia-reperfusion injury, cardiac remodeling and development of heart failure (HF). In this review we have summarized the recent studies investigating the role of TLRs in CVD and the potential for using TLRs signaling pathways as a therapeutic target in CVD.
History
Publication status
- Published
File Version
- Accepted version
Journal
Current Pharmaceutical DesignISSN
1381-6128Publisher
Bentham Science PublishersIssue
17Volume
24Page range
1887-1898Department affiliated with
- Division of Medical Education Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2018-06-12First Open Access (FOA) Date
2019-10-03First Compliant Deposit (FCD) Date
2018-06-12Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC